First-in-class oral drug approved for psoriasis conditions in Europe The European Commission has authorised apremilast (Celgene’s Otezla), a first-in-class oral drug for the treatment of chronic plaque psoriasis and psoriatic arthritis in patients who have failed first-line systemic therapies.…
Drug driving law must not be a burden for patients Patients taking medicines affected by new drug driving laws will need timely and accurate advice from pharmacists.…
Moderate drinking linked to lower risk of heart failure In a study of 15,000 adults, those who consumed up to seven drinks per week in early-to-middle age had a significantly lower risk of developing heart failure compared with their teetotal counterparts.…
Aspirin inappropriately used for CVD prevention in just over 10% of cases A survey of nearly 70,000 patients taking aspirin for primary prevention has found that, for the overall cohort, treatment was inappropriate in nearly 11.6% of cases.…
Study shows how glucocorticoids tightly control the inflammatory response IRAK-M, a key negative regulator of inflammatory pathways, may represent a new therapeutic target to suppress bacteria-induced inflammation, say researchers.…
Moorfields Eye Hospital to close its specials manufacturing facilityMoorfields Eye Hospital NHS Foundation Trust has decided to close its specials manufacturing facility in London, its board has announced.…
Eculizumab — with £340,200 price tag — gets go ahead from NICEEculizumab, dubbed “the world’s most expensive drug”, is being made available on the NHS in England following guidance from the National Institute for Health and Care Excellence.…
Older patients taking anticholinergic drugs are at risk of dementia People aged over 65 years who take some common over-the-counter or prescribed medicines for allergy, depression or an overactive bladder have an increased risk of developing dementia.…
Latest advances in hepatitis C therapy The availability of new protease inhibitors is revolutionising the treatment of hepatitis C virus infection.…
Analysis questions value of primary prevention medication for reducing CHD deaths Population-wide approaches to risk-factor control have had a far greater impact on the reduction of deaths from coronary heart disease than use of primary prevention medication.…